RIPK2 and ovarian serous adenocarcinoma: Datasets GSE30161, GSE32062 and GSE63885, which contain clinical information of patients with serous ovarian cancer, including OS and PFI data, were selected to further validate the effects of the expression of ISG15, SNCA, RIPK2, PLCG2, RHOU, TRIB2 and ELP2 on patient sensitivity to Taxol treatment (Table 2 and Supplementary Figures 1, 2, 3, 4, 5, 6).